RGD Reference Report - Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.

Authors: Wickstroem, Katrine  Hagemann, Urs B  Kristian, Alexander  Ellingsen, Christine  Sommer, Anette  Ellinger-Ziegelbauer, Heidrun  Wirnitzer, Uta  Hagelin, Else-Marie  Larsen, Aasmund  Smeets, Roger  Bjerke, Roger M  Karlsson, Jenny  Ryan, Olav B  Wengner, Antje M  Linden, Lars  Mumberg, Dominik  Cuthbertson, Alan S 
Citation: Wickstroem K, etal., Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):410-422. doi: 10.1016/j.ijrobp.2019.06.2508. Epub 2019 Jun 27.
RGD ID: 155663557
Pubmed: PMID:31255687   (View Abstract at PubMed)
DOI: DOI:10.1016/j.ijrobp.2019.06.2508   (Journal Full-text)


PURPOSE: Fibroblast growth factor receptor 2 (FGFR2) has been previously reported to be overexpressed in several types of cancer, whereas the expression in normal tissue is considered to be moderate to low. Thus, FGFR2 is regarded as an attractive tumor antigen for targeted alpha therapy. This study reports the evaluation of an FGFR2-targeted thorium-227 conjugate (FGFR2-TTC, BAY 2304058) comprising an anti-FGFR2 antibody, a chelator moiety covalently conjugated to the antibody, and the alpha particle-emitting radionuclide thorium-227. FGFR2-TTC was assessed as a monotherapy and in combination with the DNA damage response inhibitor ATRi BAY 1895344.
METHODS AND MATERIALS: The in vitro cytotoxicity and mechanism of action were evaluated by determining cell viability, the DNA damage response marker γH2A.X, and cell cycle analyses. The in vivo efficacy was determined using human tumor xenograft models in nude mice.
RESULTS: In vitro mechanistic assays demonstrated upregulation of γH2A.X and induction of cell cycle arrest in several FGFR2-expressing cancer cell lines after treatment with FGFR2-TTC. In vivo, FGFR2-TTC significantly inhibited tumor growth at a dose of 500 kBq/kg in the xenograft models NCI-H716, SNU-16, and MFM-223. By combining FGFR2-TTC with the ATR inhibitor BAY 1895344, an increased potency was observed in vitro, as were elevated levels of γH2A.X and inhibition of FGFR2-TTC-mediated cell cycle arrest. In the MFM-223 tumor xenograft model, combination of the ATRi BAY 1895344 with FGFR2-TTC resulted in significant tumor growth inhibition at doses at which the single agents had no effect.
CONCLUSIONS: The data provide a mechanism-based rationale for combining the FGFR2-TTC with the ATRi BAY 1895344 as a new therapeutic approach for treatment of FGFR2-positive tumors from different cancer indications.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
FGFR2Humancolorectal adenocarcinoma treatmentIMP human cell line in a mouse modelRGD 
Fgfr2Ratcolorectal adenocarcinoma treatmentISORGD:736865human cell line in a mouse modelRGD 
Fgfr2Mousecolorectal adenocarcinoma treatmentISORGD:736865human cell line in a mouse modelRGD 
FGFR2Humanfemale breast carcinoma treatmentIMP human cell line in a mouse modelRGD 
Fgfr2Ratfemale breast carcinoma treatmentISORGD:736865human cell line in a mouse modelRGD 
Fgfr2Mousefemale breast carcinoma treatmentISORGD:736865human cell line in a mouse modelRGD 
FGFR2Humanstomach carcinoma treatmentIMP human cell line in a mouse modelRGD 
Fgfr2Ratstomach carcinoma treatmentISORGD:736865human cell line in a mouse modelRGD 
Fgfr2Mousestomach carcinoma treatmentISORGD:736865human cell line in a mouse modelRGD 

Objects Annotated

Genes (Rattus norvegicus)
Fgfr2  (fibroblast growth factor receptor 2)

Genes (Mus musculus)
Fgfr2  (fibroblast growth factor receptor 2)

Genes (Homo sapiens)
FGFR2  (fibroblast growth factor receptor 2)


Additional Information